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sssey facts 
 A pilot study on monitoring voluntary community-based HIV testing (VCBT) was carried out in 
Ireland in 2018; this was facilitated by a new collaboration between statutory organisations, 
non-government organisations (NGOs) and other community-based organisations (CBOs) 
that provide VCBT services in Ireland, and was overseen by a multisectoral steering group.  
 All four NGO  that provided VCBT services in Ireland during 2018 participated.  
 In 2018:  
o 4,846 community-based HIV tests were carried out, using either rapid point-of-care 
testing (POCT) methods (54%), or laboratory-based testing methods (46%).   
o Eighty-four people had reactive/positive tests, corresponding to a 1.7% test reactivity 
rate. Excluding people who were previously diagnosed HIV positive, the rate was 1.5%.   
o For rapid testing, the rate was 2.4% among migrants coming from countries of high HIV 
prevalence, and 1.1% among men who have sex with men (MSM).  
o For laboratory-based testing, the rate was 5.0% among international protection 
applicants in asylum accommodation settings.  
Key points 
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Introduction  
Voluntary community-based HIV testing (VCBT) services are offered free of charge in non-
clinical community settings, and target individuals who are most at risk of HIV infection in order 
to improve HIV detection, to initiate early treatment, and to prevent onward transmission of HIV. 
VCBT is designed to be accessible for key population/at-risk groups and is provided in a range 
of settings, including mobile and outreach settings. VCBT can be carried out using either 
standard testing methods, where a blood sample is sent to a laboratory for testing, or rapid 
point-of-care testing (POCT) methods, where a trained volunteer or staff member uses a rapid 
diagnostic test and then refers a person who has a reactive test result to an HIV confirmatory 
testing service. Those whose reactive results are confirmed positive are then linked to HIV care 
and treatment services. 
 
VCBT is monitored in order to analyse trends in HIV reactive rates and to determine whether at-
risk groups are being effectively reached in the community.  
 
A pilot study to assess the feasibility of national VCBT monitoring in Ireland was undertaken in 
2018 by the HSE-Health Protection Surveillance Centre (HPSC) in partnership with HSE Social 
Inclusion and Vulnerable Groups, non-government organisations (NGOs) and other community-
based organisations (CBOs). The study had oversight from a multisectoral steering group, 
comprising investigators from HPSC; HSE Sexual Health and Crisis Pregnancy Programme 
(SHCPP); HSE Social Inclusion and Vulnerable Groups; Safetynet Primary Care Mobile Health 
and Screening Unit (MHSU); HIV Ireland; the KnowNow programme; Gender, Orientation, 
Sexual Health and HIV (GOSHH); and AIDS Care Education and Training (ACET). See 
Appendix 1 for membership of the steering group.  
 
This report presents a summary of the results for 2018 and is the first national report on VCBT 
monitoring. The results are presented as HIV test reactivity rate; this can also be called HIV 
testing prevalence rate or HIV seropositivity rate.   
 
Methods  
Data on VCBT has been collated nationally since June 2018, for testing carried out since 1 
January 2017. This report focuses on the results for 2018.  
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Participants in VCBT monitoring submit data to HPSC on a quarterly basis. A small anonymised 
case-based dataset of information is collated, including demographic characteristics, the setting 
where testing occurred, as well as information on reactive tests, indicating possible HIV 
infection, requiring further testing and confirmation. This is in line with European Centre for 
Disease Prevention and Control (ECDC) recommendations [1]. Data are collected electronically 
using a standardised template that contains predetermined answer options, provided by HPSC.  
 
Anonymised case-based data could be provided by all organisations that used rapid testing. 
Data completeness was suboptimal for three variables; whether or not the person was testing 
for the first time (completed for 92%); age (completed for 64%); and whether or not the person 
had a confirmatory HIV test (completed for 90%).  
 
Case-based data could not be provided by two out of three organisations that used standard 
laboratory-based testing, comprising 74% of laboratory-based testing. Those that could not 
provide data in case-based format provided aggregate data.  
 
 
Results  
Six organisations participated in the pilot; including all four NGOs that provide VCBT in Ireland. 
The list of all participating organisations is set out in Technical note 1.  
 
In all, there were 4,846 community-based HIV tests carried out in Ireland during 2018. Testing 
was conducted using either rapid testing (n=2,643; 54%) or laboratory-based testing methods 
(n=2,203; 46%). HIV testing methods are explained further in Technical note 4 and 5.  
 
In total, 84 individuals had reactive or positive tests, corresponding to a 1.7% HIV test reactivity 
rate. When adjusted to exclude nine individuals who were subsequently identified as previously 
diagnosed HIV positive, the rate was 1.5%.  
 
i. Rapid (point-of-care) testing 
Rapid testing was carried out in a range of high risk settings by the following NGOs: AIDSWest; 
GOSHH; the Sexual Health Centre (SHC) Cork; and via the KnowNow programme in Galway, 
Limerick, Cork and Dublin. Data could be provided in case-based format for all rapid testing. 
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Table 1 provides a summary of the demographic characteristics of all individuals tested and of 
those with reactive tests. The HIV test reactivity rate should be interpreted with caution due to 
low numbers tested (<100) among some demographic subgroups.  
 
Of 2,643 rapid tests carried out in 2018, there were 21 reactive or positive tests, corresponding 
to a 0.8% HIV test reactivity rate among those tested. Excluding two individuals who were 
subsequently identified as previously diagnosed HIV positive, the rate was 0.7%.  
 
By test setting, the highest proportion of rapid testing was carried out in bar/club settings (40%). 
The test reactivity rate was 1.2% in bar/club settings, and 1.1% in Lesbian, Gay, Bisexual and 
Transgender (LGBT) community resource centres. The rate was 1.4% in direct provision/asylum 
accommodation centre settings (centres for international protection applicants (persons seeking 
asylum)); this rate should be interpreted with caution due to low numbers tested (<100).  
 
Of those who had a rapid test, 29% (n=776) had never previously tested for HIV, 63% (n=1667) 
had previously tested and testing history was unknown for 8% (n=200). Of those who had 
reactive tests, 29% (n=6) had never previously tested for HIV and 71% (n=15) had previously 
tested. The test reactivity rate was similar among first time testers (0.8%) and repeat testers 
(0.9%).  
 
By gender, the rate was higher in males (0.9%) than in females (0.2%). Age in years could be 
provided for 64% (n=1,679) of individuals who had a rapid test; median age overall was 29 
years, for first time testers it was 26 years and for people who had tested for HIV previously it 
was 31 years. Age in years could be provided for 86% (n=18) of those with reactive tests; 
median age overall for those with reactive tests was 29 years; for first time testers it was 32 
years and for repeat testers it was 28 years.   
 
By region of origin, the test reactivity rate was 3.6% among individuals born in Latin America, 
1.9% among individuals born in sub-Saharan Africa, and 0.4% among individuals born in 
Ireland.   
 
Individuals could be reported as part of one or more key population/at-risk groups. By at-risk 
group among those with a reactive test result, the rate was 2.4% among migrants coming from 
countries of high HIV prevalence (defined as HIV prevalence >1% in the adult population, see 
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Technical note 7 for further information), and it was 1% among men who have sex with men 
(MSM). The rate was 3.6% among sex workers/escorts; however this rate should be interpreted 
with caution due to low numbers tested.  
 
Of the 21 individuals who had reactive tests, data on whether or not they had a confirmatory test 
was reported for 19, and could not be reported for two as information on confirmatory testing is 
not routinely collected by all NGOs. Of the 19 individuals with information on confirmatory 
testing, 16 underwent confirmatory testing, all of whom were confirmed HIV positive. The 
remaining three did not undergo confirmatory testing; as two were later identified as having 
been previously diagnosed with HIV and already linked to care, and one opted not to engage 
with confirmatory testing services.  
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Table 1 HIV test reactivity rate (%) and demographic characteristics, voluntary community-based rapid 
point-of-care testing in Ireland, 2018.   
    All tests Reactive 
tests 
Reactivity 
rate 
  
N N % 
Total 
 
2643 21 0.8 
Setting where test 
was provided 
Bar/ club 1046 13 1.2 
Sauna/ sex-on-premises venue 192 1 0.5 
Organisational headquarters 574 3 0.5 
LGBT community resource centre 279 3 1.1 
Emergency accommodation/ homeless service/ charity 167 0 0.0 
College/ University 142 0 0.0 
Addiction service/ resource centre 92 0 0.0 
Direct provision/ asylum accommodation centre
†
 73 1 1.4 
Family/ community resource centre 45 0 0.0 
Probation service 16 0 0.0 
Festival/ episodic event 12 0 0.0 
Other/Unknown 5 0 0.0 
First time testing for 
HIV 
Yes 776 6 0.8 
No 1667 15 0.9 
Unknown 200 0 0.0 
Gender identity
++
 Male 2173 20 0.9 
Female 456 1 0.2 
Trans male 6 0 0.0 
Trans female 2 0 0.0 
Other 6 0 0.0 
Age in years (median, range)
*
 29 (17-80) 29 (19-60)  
Region of origin Ireland 1483 6 0.4 
Western Europe 345 1 0.3 
Latin America 281 10 3.6 
South and South East Asia 109 0 0.0 
Central or Eastern Europe 148 0 0.0 
Sub-Saharan Africa 108 2 1.9 
North America
†
 54 1 1.9 
North Africa and Middle East
†
 30 1 3.3 
Other/Unknown 85 0 0.0 
Key population/at-
risk group
**
 
MSM 1724 19 1.1 
Sex with a person of opposite sex 916 2 0.2 
People who inject drugs (ever injected drugs)  115 0 0.0 
Migrant coming from a country of high HIV prevalence  127 3 2.4 
Sex worker/ escort
†
 28 1 3.6 
Undetermined (none identified from the given list) 21 0 0.0 
Unknown (question not asked or client did not want to say) 21 0 0.0 
†
Interpret rate with caution due to low numbers tested.
  
++
Gender identity is explained in
 
Technical note 6.
 
*
Age in years not available for 36% of individuals.  
**
Individuals could be reported as part of one or more key population/at-risk groups.  
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ii. Laboratory-based testing 
Of 2,203 laboratory-based tests carried out in 2018, 63 (2.9%) were positive. Excluding seven 
individuals who were subsequently identified as previously diagnosed HIV positive, the rate was 
2.6%.  
 
Testing was carried out by HIV Ireland (n=650), Safetynet Primary Care MHSU (n=567), and 
HSE Social Inclusion and Vulnerable Groups (n=986).  
 
1. HIV Ireland 
Of 650 tests provided by HIV Ireland, 548 were carried out at HIV Ireland offices in Dublin and 
102 were carried out by the Red Door Project (RDP), an outreach drug addiction service that 
operates in Drogheda. Demographic data could be provided on those tested but could not be 
provided for those who had positive tests.    
- For HIV Ireland in Dublin, 553 individuals presented (registered) for testing, of those 548 
(99%) actually tested. Fifty two percent of those tested were female. Age could not be 
provided in the format requested but could be provided in an alternative age grouping; the 
commonest age group was 26-30 years (29%). Data could not be provided on all at-risk 
groupings, but the proportion tested that was MSM could be provided (17%). Thirty seven 
percent of individuals tested were from Ireland and 19% were from Latin America.  
In all, seven (1.3%) individuals had a positive HIV test. Of those, one was confirmed 
positive, and the remaining six did not undergo confirmatory testing as they were later 
identified as having been previously diagnosed with HIV and already linked to care in 
Ireland.  
- For testing by the Red Door Project, 56% of people tested were male, the commonest age 
group was 20-24 years (24%), 75% of people tested were from Ireland, 7% were from sub-
Saharan Africa, and 7% were from North Africa and Middle East. Key population/at-risk 
group was unknown or undetermined for 80% of those tested, 11% were reported as 
migrants coming from countries of high HIV prevalence, and 9% were reported as people 
who inject drugs (PWID). In all, two (2.0%) individuals had a positive test result; 
information on confirmatory testing could not be provided.  
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2. HSE Social Inclusion and Vulnerable Groups 
HSE Social Inclusion and Vulnerable Groups could provide data for testing in Balseskin 
Reception Centre, which is Ireland’s largest accommodation centre providing specialist health 
screening for international protection applicants (persons seeking asylum) and their families in 
north Dublin. Data could be provided on the total number of individuals screened for HIV in 
Balseskin in 2018, and on the total number of individuals with a positive HIV test result. In total, 
986 individuals were screened for HIV, representing 81% of residents who were invited for 
holistic screening. Forty-nine (5.0%) individuals had a positive test result; all of whom originated 
from countries in sub-Saharan Africa. Information on whether or not individuals were previously 
diagnosed HIV positive in another country could not be provided.  
There are other testing sites in HSE for protection applicants but they are not included in HIV 
testing monitoring at this time.   
 
3. Safetynet Primary Care Mobile Health and Screening Unit 
Safetynet Primary Care is a medical charity that has been contracted by the HSE to offer VCBT 
services and medical care to international protection applicants in direct provision/asylum 
accommodation centres that have reduced capacity to manage the numbers of protection 
applicants arriving to Ireland. Safetynet also carries out active case finding for TB and blood 
borne viruses for marginalised people who do not have access to healthcare, including 
homeless people, drug users and migrants, via its MHSU which operates in various locations in 
the vicinity of homeless hostels in Dublin, Galway and Limerick. Case-based data could be 
provided by Safetynet for HIV testing carried out between 9 June 2018 and 31 December 2018. 
Of 567 tests carried out during this period, five (0.9%) individuals had a positive test result. Of 
those, three were female and two were male, and their median age was 38 years. One (male 
born in Ireland) was later identified as having been previously diagnosed with HIV and already 
linked to care. The remaining four individuals were international protection applicants tested in 
asylum accommodation settings, all originated from countries of high HIV prevalence in sub-
Saharan Africa.  
 
 
Discussion  
This is the first national report on HIV VCBT, and was facilitated through a new collaboration 
between HPSC, NGOs and other organisations that provide community HIV testing services in 
Ireland. All NGOs and participants supported this project, and made extensive efforts to 
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contribute, which, in addition to the findings of this report, resulted in the strengthening of 
valuable connections between key organisations.  
 
The proportion of first time testers was considerable (29%), and it is clear that community 
testing services are providing an important option for where individuals can have an HIV test, for 
first time testers and for repeat testers. The findings of this study indicate a 1.7% HIV test 
reactivity rate among individuals who undertook HIV VCBT in Ireland in 2018. The rate differed 
by test setting and among at-risk groups. For rapid testing by at-risk group, the rate was 2.4% 
among migrants born in countries of high HIV prevalence, and 1.1% among MSM, highlighting 
the vulnerability to HIV infection and the importance of targeted HIV VCBT services among 
these two groups. For laboratory-based testing, the HIV test positivity rate was 5.0% among 
international protection applicants at one accommodation centre, further underscoring the 
importance of providing HIV VCBT services to protection applicants and migrants coming from 
countries of high HIV prevalence so that they can be detected early and linked promptly to care 
and treatment.  
 
National data on community HIV test reactivity rates in other countries is limited. The rate in 
England in 2016 was 0.6% [3]. The European ‘HIV community-based testing practices in 
Europe’ (COBATEST) network, which monitors and evaluates HIV testing activity in community 
settings, reported an overall rate of 1.3% by 38 members in 16 European countries in 2017 [4]. 
Regional data for the Catalonia region of Spain show a rate of 2.2% in 2007 [5]. In the USA, 
CBOs in seven cities reported a rate of 1.1% for testing from 2004 to 2006 [6].   
 
Despite substantial progress towards the UNAIDS global target for 90% of people living with 
HIV (PLHIV) to have their HIV status known, ECDC reported in 2017 that a significant number 
of PLHIV in Europe and Central Asia still do not know that they are infected and almost half of 
people being diagnosed are presenting late in their infection, significantly impacting their 
chances of survival within a year of diagnosis [7, 8]. In Ireland, it is currently estimated that 13% 
of PLHIV are undiagnosed, and of the 492 people who were diagnosed with HIV in 2017, 41% 
presented late, defined as CD4 cell count less than 350 cells/µl at diagnosis or an AIDS defining 
illness at diagnosis [9, 2]. VCBT is a proven way to expand availability and improve targeting of 
HIV testing [1]. The findings of this study highlight the importance of VCBT monitoring in Ireland, 
and demonstrate that VCBT monitoring can help inform national HIV testing guidelines 
(currently under development for Ireland), and guide local and regional community HIV testing 
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strategies. This will improve targeting of HIV testing among key populations most affected by 
HIV, reduce the undiagnosed fraction, and support early treatment and diagnosis, leading to 
personal and population health benefits.  
 
There were some limitations to this study. Although the majority of data could be provided, 
completeness of some variables was suboptimal due to different data collection processes 
among organisations, including variables such as age in years, key population/at-risk group, 
history of testing for HIV, and confirmatory testing. The issue of suboptimal reporting of data on 
age was resolved by the beginning of 2019 for all rapid testing, and efforts are ongoing to 
improve completeness of other variables. Case-based data could not be provided by two 
partners who do not routinely collect case-based data; options to report case-based data are 
currently being explored. Data could not be provided by Safetynet MHSU for the first five 
months of 2018 but could be provided thereafter. Of the 84 individuals who had reactive/positive 
HIV tests, nine (11%) did not communicate their HIV-positive status at the time of testing; when 
these individuals were excluded from calculations, the HIV test reactivity rate was 1.5%. Work is 
ongoing among NGOs to encourage service users to communicate their HIV status before they 
test and also to understand reasons for not disclosing HIV status and testing when already 
known. Information on whether protection applicants in Balseskin were previously diagnosed 
HIV positive was not available; therefore the number of people previously diagnosed with HIV 
may be higher. Other HSE testing sites for protection applicants are not included in HIV testing 
monitoring at this time. Lastly, it’s not currently possible to determine the cost-effectiveness of 
VCBT in Ireland as there is currently no recommended threshold for HIV testing in community 
settings. The seropositivity threshold deemed to be cost effective for routinely offering HIV 
testing in hospital settings, based on US data, is 1 in 1000 [10].    
 
This was the first time that VCBT was monitored on a national level in Ireland; the study was 
successful due to development of strong links between key organisations and the extensive 
efforts made by participants to contribute. Following the pilot, a sustained national programme 
for VCBT monitoring was established, for community testing carried out from 1 January 2019 
onwards. HIV testing in other settings including primary care, STI clinics, prisons, self-sampling 
and self-testing, is not currently monitored on a national level. Feasibility of monitoring HIV 
testing in these other settings will be explored as part of future developments in HIV testing 
monitoring.   
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Technical notes  
1. Data on rapid testing were provided by AIDSWest, GOSHH and SHC, (inclusive of the 
outreach POCT programme known as KnowNow). Data on the targeted MSM outreach 
POCT programme in Dublin were provided by HIV Ireland.  
Data on testing using standard laboratory-based methods were provided by HIV Ireland 
(for testing at HIV Ireland offices in Dublin, and for testing carried out by the Red Door 
Project), by Safetynet Primary Care MHSU, and by HSE Social Inclusion and Vulnerable 
Groups (for Ireland’s largest asylum accommodation centre).  
2. Data included in the analysis is for data received up to 8 February 2019.  
3. Percentages are rounded up in the text and provided to one decimal place in the tables. 
4. There are two methods in routine practice for HIV testing, involving venepuncture and a 
screening assay where blood is sent to a laboratory for testing, or a rapid POCT. As per 
UK National Guidelines for HIV Testing 2008, the recommended first-line assay is one 
which tests for HIV antibody and p24 antigen simultaneously, this test is laboratory 
based and is termed a fourth generation assay [9]. A rapid test offers the advantage of a 
result from either a fingerprick or mouth swab sample within minutes. Rapid testing has 
advantages of ease of use when venepuncture is not possible, e.g. outside conventional 
healthcare settings and where a delay in obtaining a result is a disadvantage, but these 
must be weighed against the disadvantages of a test which has reduced specificity and 
reduced sensitivity versus current fourth generation laboratory tests. Due to the low 
specificity of POCT and therefore the resulting poor positive predictive value all positive 
results must be confirmed by serological tests as there will be false positives, particularly 
in lower prevalence environments. Data on confirmation testing was available for 90% of 
reactive rapid tests in this study; of those there were no false positives reported.  
5. The INSTI® Rapid HIV testing kit was used for all rapid testing in this study. The 
accuracy of the INSTI® HIV-1 Antibody test for all specimen types studied (fingerstick 
whole blood, venipuncture whole blood, plasma) is greater than or equal to 99.5% with 
the lower boundary of the 95% confidence interval (CI) greater than or equal to 99.0% 
for all sample types. This meets the FDA established requirements for approval of a 
rapid HIV test device [11].  
6. Gender identity refers to a person’s internal sense of themselves (how they feel inside) 
as being male, female, transmale, transfemale or something else. This may be different 
or the same as a person’s assigned sex at birth. Further information and resources can 
be found at the website of Transgender Equality Network Ireland (www.teni.ie). 
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7. Countries of high HIV prevalence are countries with HIV prevalence >1% in the adult 
population, as per the UNAIDS 2014 The Gap Report.  
8. The denominator used to calculate HIV test reactivity rate is of all tests carried out, not of 
individuals tested, as some individuals may have tested more than once during 2018. 
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